Forty-four patients with a diagnosis of refractory or relapsed acute myelogenous leukemia received salvage chemotherapy with high-dose cytosine arabinosine 3 g/m2 intravenously over 2 hours every 12 hours for six doses and mitoxantrone 5 mg/m2 intravenously daily for 5 days. Overall 16 patients (36%
Mitoxantrone and VP-16 in refractory acute myelogenous leukemia
✍ Scribed by P. Meyer; A. D. Ho; Th. Lipp; G. Ehninger; H. Rückle; B. Steinke; W. Kaboth; W. Hunstein
- Book ID
- 112785646
- Publisher
- Springer-Verlag
- Year
- 1986
- Tongue
- English
- Weight
- 134 KB
- Volume
- 111
- Category
- Article
- ISSN
- 1432-1335
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Twelve patients with acute lymphoblastic leukemia (ALL) were treated with aclacinomycin A (60 mg/m2/day for five days) and VP-16-213 (100 mg/m2/day). All were heavily pretreated and had relapsed or were refractory to primary or subsequent treatment. Eight patients were refractory to reinduction ther
Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days. If the day fourteen bone marrow showed residual leukemia, a second course was given at the same dose for two days. Eight patient